ProteomTech Inc.
This article was originally published in Start Up
Executive Summary
ProteomTech Inc. has developed a protocol for speeding up the protein refolding process so it can be completed in 24-to-48 hours. It's strategy for generating revenues includes contract manufacturing for the research market, a service business that may one day grow to include manufacture of protein drugs
You may also be interested in...
Protein Production Start-Ups
Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.
The Protein Production Challenge
Growth of the biopharmaceutical market is going to create critical shortages in protein manufacturing capacity with severe consequences for pharmaceutical companies' ability to deliver products and meet rising market expectations. Companies whose pipelines are heavily reliant on expression systems with limited capacity are particularly vulnerable and should now be making strategic make/buy/collaborate decisions. Indeed, in the short term as capacity tightens, contract manufacturing organizations will gain greater leverage, enabling them to negotiate more strategic business relationships with higher financial returns. In the longer term, however, innovator companies are looking beyond cell culture to alternative technologies such as transgenic animals as a future production platform, in part, because they provide greater flexibility.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.